Aspire Biopharma Holdings (ASBP) Restructuring Costs (2024 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Restructuring Costs of $395692.0 for Q2 2025, up 357.85% year-over-year from $86423.0 in Q2 2024, and up 357.85% quarter-over-quarter from $86423.0 in Q2 2024.
Aspire Biopharma Holdings (ASBP) Restructuring Costs (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Restructuring Costs for 2 consecutive years, with $395692.0 the latest figure, recorded in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Aspire Biopharma Holdings | 8.34 Mn | -3.83 Mn | -30,086.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 229,418.00 |
| Jun 30, 2025 | 395,692.00 |
| Jun 30, 2024 | 86,423.00 |